title: [Latanoprost--a new prostaglandin F2 alpha analog in therapy of glaucoma--an overview].
abstract: An ideal glaucoma drug reduces intraocular pressure profoundly and long-lastingly without known major side effects. Latanoprost, a new prostaglandin F2 alpha-analogue, indeed has these properties. However, we need long-term experience to exclude major, clinically relevant side effects. The influence of latanoprost on ocular circulation also needs further evaluation. Nevertheless, the clinician does have a new and very potent drug to reduce intraocular pressure. Literature search by Medline.
authors.affiliation: Universitäts-Augenklinik Basel.
authors.forename: C
authors.initials: C
authors.lastname: Erb
authors.forename: J
authors.initials: J
authors.lastname: Messerli
authors.forename: J
authors.initials: J
authors.lastname: Flammer
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D005901:Glaucoma / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost
vernacular_title: Latanoprost--ein neues Prostaglandin F2 alpha-Analog in der Glaukomtherapie--eine Ubersicht.